1,026 results on '"Correa-Rotter, Ricardo"'
Search Results
152. Recomendaciones para la creación, cuidado y manejo de los accesos vasculares para hemodiálisis. Documento de Posición del Comité de Nefrología Intervencionista y del Grupo de Consenso para Optimización de Accesos Vasculares de la Sociedad Latinoamericana de Nefrología e Hipertensión
- Author
-
Arvizu-Hernández, Mauricio, primary, Salgado, Octavio J., additional, Arellano-Sotelo, Jorge, additional, Barquero, Gerardo, additional, Batista, Yarima, additional, Corpus, Gerardo G., additional, Llaro, Manuel, additional, Rabanal, Katty, additional, Miranda de Menezes, Precil D., additional, García, Juan C., additional, Restrepo, César, additional, Vélez, Jaime, additional, Rosa-Diez, Guillermo, additional, Quintero, Neiro, additional, and Correa-Rotter, Ricardo, additional
- Published
- 2021
- Full Text
- View/download PDF
153. 775-P: Effects of Canagliflozin (CANA) on Major Adverse Cardiovascular Events (MACE) by Baseline EGFR: Pooled Hispanic Subgroup Analysis from the CANVAS Program and CREDENCE
- Author
-
WEIR, MATTHEW R., primary, GOGATE, JAGADISH, additional, DAMARAJU, CV, additional, CORREA-ROTTER, RICARDO, additional, and MAHAFFEY, KENNETH W., additional
- Published
- 2021
- Full Text
- View/download PDF
154. 317-OR: Efficacy and Safety of Dapagliflozin by Glycemic Status in the DAPA-CKD Trial
- Author
-
PERSSON, FREDERIK, primary, ROSSING, PETER, additional, VART, PRIYA, additional, CHERTOW, GLENN M., additional, HOU, FAN FAN, additional, MCMURRAY, JOHN J., additional, CORREA-ROTTER, RICARDO, additional, BAJAJ, HARPREET S., additional, STEFANSSON, BERGUR, additional, TOTO, ROBERT D., additional, LANGKILDE, ANNA MARIA, additional, WHEELER, DAVID C., additional, HEERSPINK, HIDDO L., additional, and GROUP, DAPA-CKD STUDY, additional
- Published
- 2021
- Full Text
- View/download PDF
155. FC 063DAPAGLIFLOZIN DECREASES ALBUMINURIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH AND WITHOUT TYPE 2 DIABETES: INSIGHTS FROM THE DAPA-CKD TRIAL
- Author
-
Jong, Niels, primary, Chertow, Glenn, additional, Hou, Fan Fan, additional, McMurray, John, additional, Correa-Rotter, Ricardo, additional, Rossing, Peter, additional, Sjöström, David, additional, Stefansson, Bergur, additional, Toto, Robert, additional, Langkilde, Anna Maria, additional, Wheeler, David C, additional, and Lambers Heerspink, Hiddo, additional
- Published
- 2021
- Full Text
- View/download PDF
156. sj-pdf-1-tae-10.1177_20420188211001160 – Supplemental material for Fibroblast growth factor 21 is associated with increased serum total antioxidant capacity and oxidized lipoproteins in humans with different stages of chronic kidney disease
- Author
-
Gómez-Sámano Miguel Ángel, Vargas-Abonce Valerie Paola, Martínez-Sánchez Froylan David, Palacios-Báez Lucía, Vera-Zertuche Juan Mauricio, Navarro-Flores María Fernanda, Morales-García Mariana Guadalupe, Fonseca-Correa Jorge Ignacio, Zuarth-Vázquez Julia María, Vega-Vega Olynka, Correa-Rotter Ricardo, Rincón-Pedrero Rodolfo, Morales-Buenrostro Luis, E., Alberú-Gómez Josefina, Ramírez-González Julia Berenice, Pacheco-Domínguez Reyna Lizette, López-Cervantes Malaquías, Mendoza-De-La-Garza María De Los Ángeles, Baeza-Arias Yolanda Victoria, Espinosa-Cuevas Ángeles, López-Carrasco Guadalupe, López-Estrada Angelina, Guillén-Pineda Luz Elizabeth, Gómez-Pérez Francisco, J., and Cuevas-Ramos Daniel
- Subjects
FOS: Clinical medicine ,111403 Paediatrics ,110306 Endocrinology ,111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified - Abstract
Supplemental material, sj-pdf-1-tae-10.1177_20420188211001160 for Fibroblast growth factor 21 is associated with increased serum total antioxidant capacity and oxidized lipoproteins in humans with different stages of chronic kidney disease by Gómez-Sámano Miguel Ángel, Vargas-Abonce Valerie Paola, Martínez-Sánchez Froylan David, Palacios-Báez Lucía, Vera-Zertuche Juan Mauricio, Navarro-Flores María Fernanda, Morales-García Mariana Guadalupe, Fonseca-Correa Jorge Ignacio, Zuarth-Vázquez Julia María, Vega-Vega Olynka, Correa-Rotter Ricardo, Rincón-Pedrero Rodolfo, Morales-Buenrostro Luis E., Alberú-Gómez Josefina, Ramírez-González Julia Berenice, Pacheco-Domínguez Reyna Lizette, López-Cervantes Malaquías, Mendoza-de-la-Garza María de los Ángeles, Baeza-Arias Yolanda Victoria, Espinosa-Cuevas Ángeles, López-Carrasco Guadalupe, López-Estrada Angelina, Guillén-Pineda Luz Elizabeth, Gómez-Pérez Francisco J. and Cuevas-Ramos Daniel in Therapeutic Advances in Endocrinology and Metabolism
- Published
- 2021
- Full Text
- View/download PDF
157. Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease
- Author
-
McMurray, John J. V., Wheeler, David C., Stefánsson, Bergur V., Jongs, Niels, Postmus, Douwe, Correa-Rotter, Ricardo, Chertow, Glenn M., Greene, Tom, Held, Claes, Hou, Fan-Fan, Mann, Johannes F. E., Rossing, Peter, Sjöström, C. David, Toto, Roberto D., Langkilde, Anna Maria, Heerspink, Hiddo J. L., McMurray, John J. V., Wheeler, David C., Stefánsson, Bergur V., Jongs, Niels, Postmus, Douwe, Correa-Rotter, Ricardo, Chertow, Glenn M., Greene, Tom, Held, Claes, Hou, Fan-Fan, Mann, Johannes F. E., Rossing, Peter, Sjöström, C. David, Toto, Roberto D., Langkilde, Anna Maria, and Heerspink, Hiddo J. L.
- Abstract
Background: Dapagliflozin reduces the risk of end-stage renal disease in patients with chronic kidney disease. We examined the relative risk of cardiovascular and renal events in these patients and the effect of dapagliflozin on either type of event, taking account of history of cardiovascular disease. Methods: In the DAPA-CKD trial (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease), 4304 participants with chronic kidney disease were randomly assigned to dapagliflozin 10 mg once daily or placebo. The primary end point was a composite of sustained decline in estimated glomerular filtration rate ≥50%, end-stage kidney disease, or kidney or cardiovascular death. The secondary end points were a kidney composite outcome (primary end point, minus cardiovascular death), the composite of hospitalization for heart failure or cardiovascular death, and all-cause death. In a prespecified subgroup analysis, we divided patients into primary and secondary prevention subgroups according to history of cardiovascular disease. Results: Secondary prevention patients (n=1610; 37.4%) were older, were more often male, had a higher blood pressure and body mass index, and were more likely to have diabetes. Mean estimated glomerular filtration rate and median urinary albumin-to-creatinine ratio were similar in the primary and secondary prevention groups. The rates of adverse cardiovascular outcomes were higher in the secondary prevention group, but kidney failure occurred at the same rate in the primary and secondary prevention groups. Dapagliflozin reduced the risk of the primary composite outcome to a similar extent in both the primary (hazard ratio, 0.61 [95% CI, 0.48–0.78]) and secondary (0.61 [0.47–0.79]) prevention groups (P-interaction=0.90). This was also true for the composite of heart failure hospitalization or cardiovascular death (0.67 [0.40–1.13] versus 0.70 [0.52–0.94], respectively; P-interaction=0.88), and all-cause mortality (0.63 [0.41–0.98] versus
- Published
- 2021
- Full Text
- View/download PDF
158. Effects of dapagliflozin on mortality in patients with chronic kidney disease : a pre-specified analysis from the DAPA-CKD randomized controlled trial.
- Author
-
Heerspink, Hiddo J L, Sjöström, C David, Jongs, Niels, Chertow, Glenn M, Kosiborod, Mikhail, Hou, Fan Fan, McMurray, John J V, Rossing, Peter, Correa-Rotter, Ricardo, Kurlyandskaya, Raisa, Stefansson, Bergur V, Toto, Robert D, Langkilde, Anna Maria, Wheeler, David C, Held, Claes, Heerspink, Hiddo J L, Sjöström, C David, Jongs, Niels, Chertow, Glenn M, Kosiborod, Mikhail, Hou, Fan Fan, McMurray, John J V, Rossing, Peter, Correa-Rotter, Ricardo, Kurlyandskaya, Raisa, Stefansson, Bergur V, Toto, Robert D, Langkilde, Anna Maria, Wheeler, David C, and Held, Claes
- Abstract
AIMS: Mortality rates from chronic kidney disease (CKD) have increased in the last decade. In this pre-specified analysis of the DAPA-CKD trial, we determined the effects of dapagliflozin on cardiovascular and non-cardiovascular causes of death. METHODS AND RESULTS: DAPA-CKD was an international, randomized, placebo-controlled trial with a median of 2.4 years of follow-up. Eligible participants were adult patients with CKD, defined as a urinary albumin-to-creatinine ratio (UACR) 200-5000 mg/g and an estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73 m2. All-cause mortality was a key secondary endpoint. Cardiovascular and non-cardiovascular death was adjudicated by an independent clinical events committee. The DAPA-CKD trial randomized participants to dapagliflozin 10 mg/day (n = 2152) or placebo (n = 2152). The mean age was 62 years, 33% were women, the mean eGFR was 43.1 mL/min/1.73 m2, and the median UACR was 949 mg/g. During follow-up, 247 (5.7%) patients died, of whom 91 (36.8%) died due to cardiovascular causes, 102 (41.3%) due to non-cardiovascular causes, and in 54 (21.9%) patients, the cause of death was undetermined. The relative risk reduction for all-cause mortality with dapagliflozin (31%, hazard ratio [HR] [95% confidence interval (CI)] 0.69 [0.53, 0.88]; P = 0.003) was consistent across pre-specified subgroups. The effect on all-cause mortality was driven largely by a 46% relative risk reduction of non-cardiovascular death (HR [95% CI] 0.54 [0.36, 0.82]). Deaths due to infections and malignancies were the most frequently occurring causes of non-cardiovascular deaths and were reduced with dapagliflozin vs. placebo. CONCLUSION: In patients with CKD, dapagliflozin prolonged survival irrespective of baseline patient characteristics. The benefits were driven largely by reductions in non-cardiovascular death.
- Published
- 2021
- Full Text
- View/download PDF
159. Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baseline
- Author
-
Stefánsson, Bergur V., Heerspink, Hiddo J. L., Wheeler, David C., Sjöström, C. David, Greasley, Peter J., Sartipy, Peter, Cain, Valerie, Correa-Rotter, Ricardo, Stefánsson, Bergur V., Heerspink, Hiddo J. L., Wheeler, David C., Sjöström, C. David, Greasley, Peter J., Sartipy, Peter, Cain, Valerie, and Correa-Rotter, Ricardo
- Abstract
Dapagliflozin is a highly selective sodium-glucose cotransporter 2 inhibitor associated with stabilization of estimated glomerular filtration rate (eGFR); reductions in glycated hemoglobin (HbA1c), systolic blood pressure, body weight, and albuminuria; and a small and consistent increase in hematocrit [1–4]. This data set is based on the associated article [5] analyzing data from 5325 patients with type 2 diabetes from 14 placebo-controlled, phase 3 (one phase 2/3), double-blind dapagliflozin treatment studies of 24–104 weeks’ duration. Data on dapagliflozin's effects (vs. placebo) on hemoglobin (Hb), hematocrit, serum albumin, serum total protein concentrations, urine albumin/creatinine ratio, eGFR, heart rate, blood pressure, body weight, and safety in patients with type 2 diabetes with and without anemia were pooled and analyzed. Patients were divided into two groups according to baseline Hb levels: anemia (Hb <13 g/dL in men and <12 g/dL in women) and no anemia. Some biomarkers associated with erythropoiesis and the presence of anemia, such as iron, transferrin, ferritin, reticulocytes, and hepcidin, were not included in the original studies and therefore data for these biomarkers were not available. Descriptive statistics were used for baseline characteristics and safety data and a longitudinal repeated-measures mixed model for efficacy data. Changes in Hb concentrations were evaluated, and the proportion of patients with baseline anemia who were no longer anemic at week 24 was determined, as was the occurrence of polycythemia (Hb >16.5 g/dL in men and >16.0 g/dL in women). Because anemia commonly occurs in patients with diabetes and chronic kidney disease [6], the data can be of value to further analyze trends in relevant physiological and pathophysiological parameters., CC BY 4.0Corresponding author: E-mail address: correarotter@gmail.com (R. Correa-Rotter).
- Published
- 2021
- Full Text
- View/download PDF
160. Early response in albuminuria and long-term kidney protection during treatment with an endothelin receptor antagonist:A prespecified analysis from the SONAR trial
- Author
-
Heerspink, Hiddo J.L., Xie, Di, Bakris, George, Correa-Rotter, Ricardo, Hou, Fan Fan, Kitzman, Dalane W., Kohan, Donald, Makino, Hirofumi, McMurray, John J.V., Perkovic, Vlado, Rossing, Peter, Parving, Hans Henrik, de Zeeuw, Dick, Heerspink, Hiddo J.L., Xie, Di, Bakris, George, Correa-Rotter, Ricardo, Hou, Fan Fan, Kitzman, Dalane W., Kohan, Donald, Makino, Hirofumi, McMurray, John J.V., Perkovic, Vlado, Rossing, Peter, Parving, Hans Henrik, and de Zeeuw, Dick
- Abstract
Background Whether early reduction in albuminuria with atrasentan treatment predicts its longterm kidney-protective effect is unknown. Methods To assess long-term effects on kidney outcomes of atrasentan versus placebo in the SONAR trial, we enrolled diabetic patients with chronic kidney disease (stage 2–4) and a urinary albumin creatinine ratio (UACR) of 300 mg/g–5000 mg/g; participants were receiving maximum tolerated renin angiotensin system inhibition. After 6 weeks exposure to 0.75 mg/day atrasentan (enrichment period), participants were randomized (stratified by UACR response during enrichment, ranging from ≤60% to >0%) to continue atrasentan or transition to placebo. Primary kidney outcome was a composite of sustained serum creatinine doubling or end-stage kidney disease. Results UACR response to atrasentan during enrichment persisted throughout the double-blind treatment phase and predicted the primary kidney outcome, whereas UACR levels with placebo remained below pre-enrichment values in the two highest UACR response strata and exceeded pre-enrichment values in the two lowest strata. As a result, early UACR response to atrasentan during enrichment was also associated with the primary kidney outcome during placebo. Accordingly, the predictive effect of early albuminuria changes during atrasentan was eliminated after placebo correction, leading to a consistent relative risk reduction for the primary kidney outcome with atrasentan compared with placebo, irrespective of the initial UACR response. The difference between atrasentan and placebo in UACR during double-blind treatment was also consistent across UACR response strata. Conclusions Our findings do not support UACR response as a causal predictor of atrasentan’s treatment effect. However, because of UACR’s variable trajectory with placebo, aspects of the trial design, day-to-day variability in albuminuria, and potential long-lasting effects of atrasentan may have contributed.
- Published
- 2021
161. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes:a prespecified analysis from the DAPA-CKD trial
- Author
-
Jongs, Niels, Greene, Tom, Chertow, Glenn M., McMurray, John J.V., Langkilde, Anna Maria, Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David, Stefansson, Bergur V., Toto, Robert D., Wheeler, David C., Heerspink, Hiddo J.L., Jongs, Niels, Greene, Tom, Chertow, Glenn M., McMurray, John J.V., Langkilde, Anna Maria, Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David, Stefansson, Bergur V., Toto, Robert D., Wheeler, David C., and Heerspink, Hiddo J.L.
- Abstract
Background: Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin significantly reduced albuminuria in patients with type 2 diabetes and normal or near-normal kidney function. Whether this effect persists in patients with chronic kidney disease with and without type 2 diabetes is unknown. We assessed the effects of dapagliflozin on albuminuria in patients with chronic kidney disease with and without type 2 diabetes in the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Methods: DAPA-CKD was a multicentre, double-blind, placebo-controlled, randomised trial done at 386 sites in 21 countries. Patients were eligible for the trial if they had chronic kidney disease, defined as an estimated glomerular filtration rate (eGFR) between 25 mL/min per 1·73 m2 and 75 mL/min per 1·73 m2 and a urinary albumin-to-creatinine ratio (UACR) between 200 mg/g and 5000 mg/g (22·6 to 565·6 mg/mmol). Participants were randomly assigned to dapagliflozin 10 mg (AstraZeneca; Gothenburg, Sweden) once daily or matching placebo, in accordance with the sequestered, fixed randomisation schedule, using balanced blocks to ensure an approximate 1:1 ratio. Change in albuminuria was a pre-specified exploratory outcome of DAPA-CKD. Regression in UACR stage, defined as a transition from macroalbuminuria (≥300 mg/g) to microalbuminuria or normoalbuminuria (<300 mg/g), and progression in UACR stage, defined as a transition from less than 3000 mg/g to 3000 mg/g or greater, were additional discrete endpoints. The trial is registered with ClinicalTrials.gov, NCT03036150. Findings: Between Feb 2, 2017, and April 3, 2020, 4304 patients were recruited and randomly assigned to either dapagliflozin (n=2152) or placebo (n=2152). Median UACR was 949 mg/g (IQR 477 to 1885). Overall, compared with placebo, dapagliflozin reduced geometric me
- Published
- 2021
162. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes:a prespecified analysis from the DAPA-CKD trial
- Author
-
Heerspink, Hiddo J.L., Jongs, Niels, Chertow, Glenn M., Langkilde, Anna Maria, McMurray, John J.V., Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David, Stefansson, Bergur V., Toto, Robert D., Wheeler, David C., Greene, Tom, Heerspink, Hiddo J.L., Jongs, Niels, Chertow, Glenn M., Langkilde, Anna Maria, McMurray, John J.V., Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David, Stefansson, Bergur V., Toto, Robert D., Wheeler, David C., and Greene, Tom
- Abstract
Background: Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified analysis, we assessed the effect of dapagliflozin on the rate of change in estimated glomerular filtration rate (eGFR)—ie, the eGFR slope. Methods: DAPA-CKD was a randomised controlled trial that enrolled participants aged 18 years or older, with or without type 2 diabetes, with a urinary albumin-to-creatinine ratio (UACR) of 200–5000 mg/g, and an eGFR of 25–75 mL/min per 1·73m2. Participants were randomly assigned (1:1) to oral dapagliflozin 10 mg once daily or placebo, added to standard care. In this pre-specified analysis, we analysed eGFR slope using mixed-effect models with different slopes from baseline to week 2 (acute eGFR decline), week 2 to end of treatment (chronic eGFR slope), and baseline to end of treatment (total eGFR slope). DAPA-CKD is registered with ClinicalTrials.gov, NCT03036150, and is now complete. Findings: Between Feb 2, 2017, and April 3, 2020, 4304 participants were recruited, of whom 2152 (50%) were assigned to dapagliflozin and 2152 (50%) were assigned to placebo. At baseline, the mean age was 62 years (SD 12), 1425 (33·1%) participants were women, 2906 (67·5%) participants had type 2 diabetes. The median on-treatment follow-up was 2·3 years (IQR 1·8–2·6). From baseline to the end of treatment, dapagliflozin compared with placebo slowed eGFR decline by 0·95 mL/min per 1·73 m2 per year (95% CI 0·63 to 1·27) in the overall cohort. Between baseline and week 2, dapagliflozin compared with placebo resulted in an acute eGFR decline of 2·61 mL/min per 1·73 m2 (2·16 to 3·06) in patients with type 2 diabetes and 2·01 mL/min per 1·73 m2 (1·36 to 2·66) in those without type 2 diabetes. Between week 2 and end of treatment, dapagliflozin compared with placebo reduced the mean rate of eGFR decline by a greater amount in patients
- Published
- 2021
163. Effects of dapagliflozin in stage 4 chronic kidney disease
- Author
-
Chertow, Glenn M., Vart, Priya, Jongs, Niels, Toto, Robert D., Gorriz, Jose Luis, Hou, Fan Fan, McMurray, John J.V., Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David, Stefánsson, Bergur V., Langkilde, Anna Maria, Wheeler, David C., Heerspink, Hiddo J.L., Chertow, Glenn M., Vart, Priya, Jongs, Niels, Toto, Robert D., Gorriz, Jose Luis, Hou, Fan Fan, McMurray, John J.V., Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David, Stefánsson, Bergur V., Langkilde, Anna Maria, Wheeler, David C., and Heerspink, Hiddo J.L.
- Abstract
Background In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPACKD) randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in patients with CKD with or without type 2 diabetes. Methods Adultswith eGFR of 25-75 ml/min per 1.73m2 and urinary albumin-to-creatinine ratio of 200-5000 mg/g had been randomized to receive dapagliflozin 10 mg/d or placebo.Here,we conducted a prespecified analysis of dapagliflozin's effects in patientswith stage 4 CKD (eGFR,30ml/min per 1.73m2) at baseline. The primary end pointwas a composite of time to$50%sustained decline in eGFR, ESKD, or kidney or cardiovascular death. Secondary end points were a kidney composite (same as the primary end point but without cardiovascular death), a composite of cardiovascular death or heart failure hospitalization, and all-cause death. Results A total of 293 participants with stage 4 CKD received dapagliflozin and 331 received placebo. Patients with stage 4 CKD randomized to dapagliflozin experienced a 27% (95% confidence interval [95% CI]: 22 to 47%) reduction in the primary composite endpoint, and 29% (22 to 51%), 17% (253 to 55%), and 32% (221 to 61%) reductions in the kidney, cardiovascular and mortality endpoints, respectively, relative to placebo. Interaction P-valueswere 0.22, 0.13, 0.63, and 0.95, respectively, comparingCKDstages 4 versus 2/3. The eGFR slope declined by 2.15 and 3.38 ml/min per 1.73m2 per year in the dapagliflozin and placebo groups, respectively (P50.005). Patients treated with dapagliflozin or placebo had similar rates of serious adverse events and adverse events of interest. Conclusions Among patientswith stage 4 CKD and albuminuria, the effects of dapagliflozinwere consistent with those observed in the DAPA-CKD trial overall, with no evidence of increased risks.
- Published
- 2021
164. Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status:A Prespecified Analysis From the DAPA-CKD Trial
- Author
-
Persson, Frederik, Rossing, Peter, Vart, Priya, Chertow, Glenn M., Hou, Fan Fan, Jongs, Niels, McMurray, John J., Correa-Rotter, Ricardo, Bajaj, Harpreet S., Stefansson, Bergur, Toto, Robert D., Langkilde, Anna Maria, Wheeler, David C., Heerspink, Hiddo J. L., Persson, Frederik, Rossing, Peter, Vart, Priya, Chertow, Glenn M., Hou, Fan Fan, Jongs, Niels, McMurray, John J., Correa-Rotter, Ricardo, Bajaj, Harpreet S., Stefansson, Bergur, Toto, Robert D., Langkilde, Anna Maria, Wheeler, David C., and Heerspink, Hiddo J. L.
- Abstract
OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular outcomes with dapagliflozin versus placebo in participants with chronic kidney disease (CKD) with and without diabetes. We compared outcomes according to baseline glycemic status. RESEARCH DESIGN AND METHODS We enrolled participants with CKD, estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73 m(2), and urinary albumin-to-creatinine ratio 200-5,000 mg/g. The primary composite end point was sustained eGFR decline >= 50%, end-stage kidney disease, or kidney or cardiovascular death. RESULTS Of 4,304 participants, 738 had normoglycemia, 660 had prediabetes, and 2,906 had type 2 diabetes. The effect of dapagliflozin on the primary outcome was consistent (P for interaction = 0.19) in normoglycemia (hazard ratio [HR] 0.62 [95% CI 0.39, 1.01]), prediabetes (HR 0.37 [0.21, 0.66]), and type 2 diabetes (HR 0.64 [0.52, 0.79]). We found no evidence for effect modification on any outcome. Adverse events were similar, with no major hypoglycemia or ketoacidosis in participants with normoglycemia or prediabetes. CONCLUSIONS Dapagliflozin safely reduced kidney and cardiovascular events independent of baseline glycemic status.
- Published
- 2021
165. Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease
- Author
-
McMurray, John J V, Wheeler, David C, Stefánsson, Bergur V, Jongs, Niels, Postmus, Douwe, Correa-Rotter, Ricardo, Chertow, Glenn M, Greene, Tom, Held, Claes, Hou, Fan-Fan, Mann, Johannes F E, Rossing, Peter, Sjöström, C David, Toto, Roberto D, Langkilde, Anna Maria, Heerspink, Hiddo J L, McMurray, John J V, Wheeler, David C, Stefánsson, Bergur V, Jongs, Niels, Postmus, Douwe, Correa-Rotter, Ricardo, Chertow, Glenn M, Greene, Tom, Held, Claes, Hou, Fan-Fan, Mann, Johannes F E, Rossing, Peter, Sjöström, C David, Toto, Roberto D, Langkilde, Anna Maria, and Heerspink, Hiddo J L
- Abstract
BACKGROUND: Dapagliflozin reduces the risk of end-stage renal disease in patients with chronic kidney disease. We examined the relative risk of cardiovascular and renal events in these patients and the effect of dapagliflozin on either type of event, taking account of history of cardiovascular disease.METHODS: In the DAPA-CKD trial (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease), 4304 participants with chronic kidney disease were randomly assigned to dapagliflozin 10 mg once daily or placebo. The primary end point was a composite of sustained decline in estimated glomerular filtration rate ≥50%, end-stage kidney disease, or kidney or cardiovascular death. The secondary end points were a kidney composite outcome (primary end point, minus cardiovascular death), the composite of hospitalization for heart failure or cardiovascular death, and all-cause death. In a prespecified subgroup analysis, we divided patients into primary and secondary prevention subgroups according to history of cardiovascular disease.RESULTS: Secondary prevention patients (n=1610; 37.4%) were older, were more often male, had a higher blood pressure and body mass index, and were more likely to have diabetes. Mean estimated glomerular filtration rate and median urinary albumin-to-creatinine ratio were similar in the primary and secondary prevention groups. The rates of adverse cardiovascular outcomes were higher in the secondary prevention group, but kidney failure occurred at the same rate in the primary and secondary prevention groups. Dapagliflozin reduced the risk of the primary composite outcome to a similar extent in both the primary (hazard ratio, 0.61 [95% CI, 0.48-0.78]) and secondary (0.61 [0.47-0.79]) prevention groups (P-interaction=0.90). This was also true for the composite of heart failure hospitalization or cardiovascular death (0.67 [0.40-1.13] versus 0.70 [0.52-0.94], respectively; P-interaction=0.88), and all-cause mortality (0.63 [0.
- Published
- 2021
166. Iniciativas para reducir la sal alimentaria en la Región de las Américas
- Author
-
Campbell, Norm R.C., Correa-Rotter, Ricardo, Legowski, Barbara, and Legetic, Branka
- Published
- 2012
167. OPINION: Hyperosmolarity drives hypertension and CKD—water and salt revisited
- Author
-
Johnson, Richard J., Rodriguez-Iturbe, Bernardo, Roncal-Jimenez, Carlos, Lanaspa, Miguel A., Ishimoto, Takuji, Nakagawa, Takahiko, Correa-Rotter, Ricardo, Wesseling, Catharina, Bankir, Lise, and Sanchez-Lozada, Laura G.
- Published
- 2014
- Full Text
- View/download PDF
168. Tubular urinary biomarkers do not identify aetiology of acute kidney injury in kidney transplant recipients
- Author
-
RAMIREZ-SANDOVAL, JUAN C, BARRERA-CHIMAL, JONATAN, SIMANCAS, PERLA E, CORREA-ROTTER, RICARDO, BOBADILLA, NORMA A, and MORALES-BUENROSTRO, LUIS E
- Published
- 2014
- Full Text
- View/download PDF
169. 64 - Peritoneal Dialysis
- Author
-
Correa-Rotter, Ricardo, Mehrotra, Rajnish, and Saxena, Anjali Bhatt
- Published
- 2020
- Full Text
- View/download PDF
170. Chapter 9 - Ethnicity and Chronic Kidney Disease in Disadvantaged Populations—An International Perspective
- Author
-
Correa-Rotter, Ricardo, García-García, Guillermo, Chávez-Iñiguez, Jonathan, and Ramírez-Sandoval, Juan C.
- Published
- 2020
- Full Text
- View/download PDF
171. Anemia, overhydration, and lower muscle strength in hemodialysis patients with protein-energy wasting.
- Author
-
Chávez-Mendoza, Carlos A., Martínez-Rueda, Armando J., Ortega-Vargas, José L., Becerra-Laparra, Ivonne K., Ardavín-Ituarte, Juan M., Correa-Rotter, Ricardo, Ramírez-Sandoval, Juan C., and Vega-Vega, Olynka
- Published
- 2022
- Full Text
- View/download PDF
172. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
- Author
-
Waijer, Simke W., Vart, Priya, Cherney, David Z. I., Chertow, Glenn M., Jongs, Niels, Langkilde, Anna Maria, Mann, Johannes F. E., Mosenzon, Ofri, McMurray, John J. V., Rossing, Peter, Correa-Rotter, Ricardo, Stefansson, Bergur V., Toto, Robert D., Wheeler, David C., and Heerspink, Hiddo J. L.
- Abstract
Aims/hypothesis: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney disease, hospitalised heart failure or cardiovascular death, and death from all causes in patients with chronic kidney disease (CKD) with or without type 2 diabetes. Patients with more severe CKD are at higher risk of kidney failure, cardiovascular events and all-cause mortality. In this post hoc analysis, we assessed the efficacy and safety of dapagliflozin according to baseline Kidney Disease Improving Global Outcomes (KDIGO) risk categories. Methods: DAPA-CKD was a double-blind, placebo-controlled trial that randomised patients with an eGFR of 25–75 ml min
−1 [1.73 m]−2 and urinary albumin/creatinine ratio (UACR) of ≥22.6 and <565.0 mg/mmol (200–5000 mg/g) to dapagliflozin 10 mg/day or placebo. The primary endpoint was a composite of ≥50% reduction in eGFR, end-stage kidney disease (ESKD), and death from a kidney or cardiovascular cause. Secondary endpoints included a kidney composite (≥50% reduction in eGFR, ESKD and death from a kidney cause), a cardiovascular composite (heart failure hospitalisation or cardiovascular death), and death from all causes. We used Cox proportional hazards regression analyses to assess relative and absolute effects of dapagliflozin across KDIGO risk categories. Results: Of the 4304 participants in the DAPA-CKD study, 619 (14.4%) were moderately high risk, 1349 (31.3%) were high risk and 2336 (54.3%) were very high risk when categorised by KDIGO risk categories at baseline. Dapagliflozin reduced the hazard of the primary composite (HR 0.61; 95% CI 0.51, 0.72) and secondary endpoints consistently across KDIGO risk categories (all p for interaction >0.09). Absolute risk reductions for the primary outcome were also consistent irrespective of KDIGO risk category (p for interaction 0.26). Analysing patients with and without type 2 diabetes separately, the relative risk reduction with dapagliflozin in terms of the primary outcome was consistent across subgroups of KDIGO risk categories. The relative frequencies of adverse events and serious adverse events were also similar across KDIGO risk categories. Conclusion/interpretations: The consistent benefits of dapagliflozin on kidney and cardiovascular outcomes across KDIGO risk categories indicate that dapagliflozin is efficacious and safe across a wide spectrum of kidney disease severity. Trial registration: ClinicalTrials.gov NCT03036150. Funding: The study was funded by AstraZeneca. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
173. Clinical factors associated with early and persistent hypocalcaemia after parathyroidectomy in patients on dialysis with severe hyperparathyroidism
- Author
-
Fonseca‐Correa, Jorge I., primary, Nava‐Santana, Carlos, additional, Tamez‐Pedroza, Luis, additional, Paz‐Cortes, Armando, additional, Santillan‐Ceron, Airy, additional, Rojas‐Concha, Luis J., additional, Pantoja‐Millán, Juan Pablo, additional, Sierra‐Salazar, Mauricio, additional, Velazquez‐Fernández, David, additional, Herrera, Miguel F., additional, Correa‐Rotter, Ricardo, additional, and Ramirez‐Sandoval, Juan C., additional
- Published
- 2021
- Full Text
- View/download PDF
174. The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial
- Author
-
Parfrey, Patrick S., Chertow, Glenn M., Block, Geoffrey A., Correa-Rotter, Ricardo, Drüeke, Tilman B., Floege, Jürgen, Herzog, Charles A., London, Gerard M., Mahaffey, Kenneth W., Moe, Sharon M., Wheeler, David C., Dehmel, Bastian, Trotman, Marie-Louise, Modafferi, Dennis M., and Goodman, William G.
- Published
- 2013
175. Dapagliflozin in Patients with Chronic Kidney Disease
- Author
-
Heerspink, Hiddo J.L., Stefánsson, Bergur V., Correa-Rotter, Ricardo, Chertow, Glenn M., Greene, Tom, Hou, Fan-Fan, Mann, Johannes F.E., McMurray, John J.V., Lindberg, Magnus, Rossing, Peter, Sjöström, C. David, Toto, Roberto D., Langkilde, Anna-Maria, Wheeler, David C., Cruzado, Josep Ma., Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), and Groningen Kidney Center (GKC)
- Subjects
Male ,Kidney Failure, Chronic/mortality ,Benzhydryl Compounds/adverse effects ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,Glomerular Filtration Rate/drug effects ,law.invention ,chemistry.chemical_compound ,0302 clinical medicine ,Randomized controlled trial ,Glucosides ,law ,Diabetic Nephropathies ,030212 general & internal medicine ,Dapagliflozin ,Kidney ,Diabetis ,Kidney diseases ,Diabetes ,EMPAGLIFLOZIN ,General Medicine ,Middle Aged ,medicine.anatomical_structure ,Cardiovascular Diseases ,Regression Analysis ,Female ,Glomerular Filtration Rate ,medicine.medical_specialty ,Finerenone ,Renal Insufficiency, Chronic/complications ,CARDIOVASCULAR OUTCOMES ,Glucosides/adverse effects ,03 medical and health sciences ,Internal medicine ,Diabetes mellitus ,Empagliflozin ,medicine ,Humans ,Benzhydryl compounds ,Cardiovascular Diseases/etiology ,Benzhydryl Compounds ,Renal Insufficiency, Chronic ,Sodium-Glucose Transporter 2 Inhibitors ,Aged ,urogenital system ,business.industry ,Diabetes Mellitus, Type 2/complications ,Glucòsids ,Sodium-Glucose Transporter 2 Inhibitors/adverse effects ,medicine.disease ,Diabetes Mellitus, Type 2 ,chemistry ,Diabetic Nephropathies/drug therapy ,Kidney Failure, Chronic ,Malalties del ronyó ,business ,Kidney disease - Abstract
Background: \ud Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.\ud Methods: \ud We randomly assigned 4304 participants with an estimated glomerular filtration rate (GFR) of 25 to 75 ml per minute per 1.73 m2 of body-surface area and a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 200 to 5000 to receive dapagliflozin (10 mg once daily) or placebo. The primary outcome was a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes.\ud Results:\ud The independent data monitoring committee recommended stopping the trial because of efficacy. Over a median of 2.4 years, a primary outcome event occurred in 197 of 2152 participants (9.2%) in the dapagliflozin group and 312 of 2152 participants (14.5%) in the placebo group (hazard ratio, 0.61; 95% confidence interval [CI], 0.51 to 0.72; P
- Published
- 2020
176. Desarrollo de una herramienta de tamizaje para consumo elevado de sodio en una población adulta mexicana
- Author
-
Miranda-Alatriste, Paola Vanessa, Colín Ramírez, Eloísa, Guillén Hernández, Marymar, Rivera Mancía, Susana, Cartas Rosado, Raúl, Espinosa-Cuevas, Ángeles, Correa-Rotter, Ricardo, and Vallejo, Maite
- Subjects
Sal ,Validación ,Cuestionario de frecuencia de alimentos ,Food frequency questionnaire ,Salt ,Validation ,Dieta ,Diet - Abstract
Resumen Introducción: la excreción de sodio en orina de 24 horas es el método de referencia para evaluar la ingesta de sodio; sin embargo, se requieren herramientas que puedan aplicarse de manera más práctica tanto en el ámbito clínico como en el poblacional. Objetivos: desarrollar y evaluar un cuestionario autoadministrable de frecuencia de consumo de alimentos ricos en sodio (CFCA-S) como herramienta de tamizaje para consumo elevado de sodio en una población adulta de la Ciudad de México. Métodos: se desarrolló un CFCA-S con 28 categorías de alimentos ricos en sodio y su sistema de puntuación respectivo. El percentil 75 del puntaje total del CFCA-S se probó como punto de corte para clasificar a las personas con alto consumo de sodio a dos niveles (≥ 2.000 y ≥ 3.000 mg/día), considerando la excreción urinaria de sodio en 24 horas como método de referencia. Resultados: se incluyeron 95 participantes (mediana de edad: 39 [percentiles 25-75: 26-46] años; hombres: 39 [41,1%]). Un puntaje total de 51,2 en el CFCA-S mostró una sensibilidad del 31,6% (intervalo de confianza [IC] 95%: 19,1-47,5), una especificidad del 78,9% (IC 95%: 66,7-87,5), valor predictivo positivo del 50% (IC 95%: 31,4-68,6) y valor predictivo negativo del 63,4% (IC 95%: 51,8-73,6), para clasificar a las personas con consumo de sodio ≥ 3.000 mg/día. Un puntaje ≥ 51,2 se asoció significativamente con una ingesta de sodio ≥ 3.000 mg/día, resultando en una razón de momios de 3,12 (IC 95%: 1,03-9,44, p = 0,04), después de ajustar por sexo, edad e índice de masa corporal (IMC). Conclusiones: el CFCA-S es una herramienta práctica, factible de aplicarse y útil para identificar a personas en riesgo de tener un consumo elevado de sodio. Abstract Background: twenty-four-hour urinary sodium excretion is the reference method to assess sodium intake; however, tools that can be more easily applied in the clinical and population setting are needed. Objectives: to develop and evaluate a self-administered high-sodium food frequency questionnaire (abbreviated to CFCA-S in Spanish) as a screening tool for high sodium intake in an adult Mexico City population. Methods: a CFCA-S including 28 sodium-rich food categories and a scoring system were developed. The 75 percentile for the total score was tested as cut-off point to classify high sodium consumers at two different levels (≥ 2,000 and ≥ 3,000 mg/day) against 24-h urinary sodium excretion as reference method. Results: ninety-five participants were included (median age: 39 [25th-75th percentiles: 26-46] years; men: 39 [41.1%]). A total score of 51.2 in the CFCA-S showed a sensitivity of 31.6% (95% confidence interval [CI]: 19.1-47.5), specificity of 78.9 (95% CI: 66.7-87.5), positive predictive value of 50% (95% CI: 31.4-68.6) and negative predictive value of 63.4% (95% CI: 51.8-73.6) to classify high-sodium consumers at a level of intake ≥ 3,000 mg/day. A total score ≥ 51.2 was significantly associated with a sodium intake ≥ 3,000 mg/day, observing an odds ratio of 3.12 (CI 95%: 1.03-9.44, p = 0.04), after adjusting by sex, age, and body mass index. Conclusions: the sodium CFCA-S developed in this study is a practical, feasible and useful tool to identify individuals at greater risk of having a high sodium intake.
- Published
- 2020
177. Renoprotective and antihypertensive effects of S-allylcysteine in 5/6 nephrectomized rats
- Author
-
Cruz, Cristino, Correa-Rotter, Ricardo, Sanchez-Gonzalez, Dolores Javier, Hernandez-Pando, Rogelio, Maldonado, Perla D., Martinez-Martinez, Claudia Maria, Medina-Campos, Omar Noel, Tapia, Edilia, Aguilar, Diana, Chirino, Yolanda I., and Pedraza-Chaverri, Jose
- Subjects
Allylic compounds -- Influence ,Allylic compounds -- Physiological aspects ,Nephrectomy -- Influence ,Nephrectomy -- Physiological aspects ,Kidneys -- Properties ,Rats -- Physiological aspects ,Rattus -- Physiological aspects ,Biological sciences - Abstract
Progressive renal damage and hypertension are associated with oxidative and nitrosative stress. On the other hand, S-allylcysteine (SAC), the most abundant organosulfur compound in aged garlic extract (AG), has antioxidant properties. The effects of SAC and AG on blood pressure, renal damage, and oxidative and nitrosative stress were studied in five-sixths nephrectomized rats treated with SAC (200 mg/kg ip) and AG (1.2 ml/kg ip) every other day for 30 days. Proteinuria and serum creatinine and blood urea nitrogen concentrations were measured on days 0, 5, 10, 15, and 30, and systolic blood pressure was recorded on days 0, 15, and 30. The degree of glomerulosclerosis and tubulointerstitial damage, the immunostaining for inducible nitric oxide synthase, 3-nitrotyrosine, poly(ADP-ribose), and the subunits of NADPH oxidase [p22.sup.phox] and [gp91.sup.phox], and the activity of SOD were determined on day 30. SAC and AG reduced hypertension, renal damage, and the abundance of inducible nitric oxide synthase, 3-nitrotyrosine, poly(ADP-ribose), [p22.sup.phox], and [gp91.sup.phox] and increased SOD activity. Our data suggest that the antihypertensive and renoprotective effects of SAC and AG are associated with their antioxidant properties and that they may be used to ameliorate hypertension and delay the progression of renal damage. aged garlic; renal injury; hypertension; superoxide anion
- Published
- 2007
178. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
- Author
-
Heerspink, Hiddo J L, Stefansson, Bergur V, Chertow, Glenn M, Correa-Rotter, Ricardo, Greene, Tom, Hou, Fan-Fan, Lindberg, Magnus, McMurray, John, Rossing, Peter, Toto, Roberto, Langkilde, Anna Maria, Wheeler, David C, Held, Claes, Heerspink, Hiddo J L, Stefansson, Bergur V, Chertow, Glenn M, Correa-Rotter, Ricardo, Greene, Tom, Hou, Fan-Fan, Lindberg, Magnus, McMurray, John, Rossing, Peter, Toto, Roberto, Langkilde, Anna Maria, Wheeler, David C, and Held, Claes
- Abstract
BACKGROUND: Recent cardiovascular outcome trials have shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors slow the progression of chronic kidney disease (CKD) in patients with type 2 diabetes at high cardiovascular risk. Whether these benefits extend to CKD patients without type 2 diabetes or cardiovascular disease is unknown. The Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) trial (NCT03036150) will assess the effect of the SGLT2 inhibitor dapagliflozin on renal and cardiovascular events in a broad range of patients with CKD with and without diabetes. METHODS: DAPA-CKD is a randomized, double-blind, placebo-controlled, trial in which ∼4300 patients with CKD Stages 2-4 and elevated urinary albumin excretion will be enrolled. The vast majority will be receiving a maximum tolerated dose of a renin-angiotensin system inhibitor at enrolment. RESULTS: After a screening assessment, eligible patients with a urinary albumin:creatinine ratio ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 are randomly assigned to placebo or dapagliflozin 10 mg/day. Enrolment is monitored to ensure that at least 30% of patients do not have diabetes and that no more than 10% have an eGFR >60 mL/min/1.73 m2. The primary endpoint is a composite of a sustained decline in eGFR of ≥50%, end-stage renal disease, renal death or cardiovascular death. The trial will conclude when 681 primary renal events have occurred, providing 90% power to detect a 22% relative risk reduction (α level of 0.05). CONCLUSION: DAPA-CKD will determine whether the SGLT2 inhibitor dapagliflozin, added to guideline-recommended therapies, safely reduces the rate of renal and cardiovascular events in patients across multiple CKD stages with and without diabetes.
- Published
- 2020
- Full Text
- View/download PDF
179. The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment : a post hoc analysis
- Author
-
Scholtes, Rosalie A., van Raalte, Daniël H., Correa-Rotter, Ricardo, Toto, Robert D., Heerspink, Hiddo J. L., Cain, Valerie, Sjöström, C. David, Sartipy, Peter, Stefánsson, Bergur V., Scholtes, Rosalie A., van Raalte, Daniël H., Correa-Rotter, Ricardo, Toto, Robert D., Heerspink, Hiddo J. L., Cain, Valerie, Sjöström, C. David, Sartipy, Peter, and Stefánsson, Bergur V.
- Abstract
Aims: Renin-angiotensin system inhibitors (RASi) are the most effective treatments for diabetic kidney disease but significant residual renal risk remains, possibly because of other mechanisms of kidney disease progression unrelated to RAS that may be present. Sodium-glucose co-transporter-2 inhibitors reduce albuminuria and may complement RASi by offering additional renal protection. This post hoc analysis investigated the effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes (T2D) with increased albuminuria treated with or without RASi at baseline. Materials and methods: We evaluated the effects of dapagliflozin 10 mg/day over 12–24 weeks across 13 placebo-controlled studies in patients with T2D with a urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g at baseline. Patients were divided into two subgroups based on treatment with or without RASi at baseline. Results: Compared with patients with RASi at baseline (n = 957), patients without RASi (n = 302) were younger, had a shorter duration of diabetes (7 vs. 12 years), higher estimated glomerular filtration rate (eGFR) and lower UACR, serum uric acid (sUA), body weight and systolic blood pressure. Placebo-adjusted treatment effects of dapagliflozin on UACR, eGFR, glycated haemoglobin and haematocrit over 24 weeks were similar across groups. Mean reductions in body weight and sUA were more distinct in patients without RASi treatment at baseline. Conclusions: Treatment with dapagliflozin over 24 weeks provides similar clinically relevant improvements in metabolic and haemodynamic parameters, and similar reductions in UACR, in patients with T2D with elevated albuminuria treated with or without RASi at baseline. © 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
- Published
- 2020
- Full Text
- View/download PDF
180. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial : baseline characteristics
- Author
-
Wheeler, David C., Stefansson, Bergur, V, Batiushin, Mikhail, Bilchenko, Oleksandr, Cherney, David Z., I, Chertow, Glenn M., Douthat, Walter, Dwyer, Jamie P., Escudero, Elizabeth, Pecoits-Filho, Roberto, Furuland, Hans, Gorriz, Jose Luis, Greene, Tom, Haller, Hermann, Hou, Fan Fan, Kang, Shin-Wook, Isidto, Rey, Khullar, Dinesh, Mark, Patrick B., McMurray, John J., V, Kashihara, Naoki, Nowicki, Michal, Persson, Frederik, Correa-Rotter, Ricardo, Rossing, Peter, Toto, Robert D., Umanath, Kausik, Van Bui, Pham, Wittmann, Istvan, Lindberg, Magnus, Sjostrom, C. David, Langkilde, Anna Maria, Heerspink, Hiddo J. L., Wheeler, David C., Stefansson, Bergur, V, Batiushin, Mikhail, Bilchenko, Oleksandr, Cherney, David Z., I, Chertow, Glenn M., Douthat, Walter, Dwyer, Jamie P., Escudero, Elizabeth, Pecoits-Filho, Roberto, Furuland, Hans, Gorriz, Jose Luis, Greene, Tom, Haller, Hermann, Hou, Fan Fan, Kang, Shin-Wook, Isidto, Rey, Khullar, Dinesh, Mark, Patrick B., McMurray, John J., V, Kashihara, Naoki, Nowicki, Michal, Persson, Frederik, Correa-Rotter, Ricardo, Rossing, Peter, Toto, Robert D., Umanath, Kausik, Van Bui, Pham, Wittmann, Istvan, Lindberg, Magnus, Sjostrom, C. David, Langkilde, Anna Maria, and Heerspink, Hiddo J. L.
- Abstract
Background. The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. Methods. In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) <= 200mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75mL/min/1.73m(2) were randomized to dapagliflozin 10mg once daily or placebo. Mean eGFR was 43.1mL/min/1.73m(2) and median UACR was 949 mg/g (108mg/mmol). Results. Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n = 2510) were ischaemic/hypertensive nephropathy (n = 687) and chronic glomerulonephritis (n = 695), of which immunoglobulin A nephropathy (n = 270) was the most common. A total of 4174 participants (97%) were receiving an angiotensinconverting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1mL/min/1.73m(2) lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR). Conclusions. Participants with a wide range of underlying kidney diseases receiving renin-angiotensin system blocking therapy
- Published
- 2020
- Full Text
- View/download PDF
181. Dapagliflozin in Patients with Chronic Kidney Disease
- Author
-
Heerspink, Hiddo J L, Stefánsson, Bergur V, Correa-Rotter, Ricardo, Chertow, Glenn M, Greene, Tom, Hou, Fan-Fan, Mann, Johannes F E, McMurray, John J V, Lindberg, Magnus, Rossing, Peter, Sjöström, C David, Toto, Roberto D, Langkilde, Anna-Maria, Wheeler, David C, Heerspink, Hiddo J L, Stefánsson, Bergur V, Correa-Rotter, Ricardo, Chertow, Glenn M, Greene, Tom, Hou, Fan-Fan, Mann, Johannes F E, McMurray, John J V, Lindberg, Magnus, Rossing, Peter, Sjöström, C David, Toto, Roberto D, Langkilde, Anna-Maria, and Wheeler, David C
- Abstract
BACKGROUND: Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.METHODS: We randomly assigned 4304 participants with an estimated glomerular filtration rate (GFR) of 25 to 75 ml per minute per 1.73 m2 of body-surface area and a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 200 to 5000 to receive dapagliflozin (10 mg once daily) or placebo. The primary outcome was a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes.RESULTS: The independent data monitoring committee recommended stopping the trial because of efficacy. Over a median of 2.4 years, a primary outcome event occurred in 197 of 2152 participants (9.2%) in the dapagliflozin group and 312 of 2152 participants (14.5%) in the placebo group (hazard ratio, 0.61; 95% confidence interval [CI], 0.51 to 0.72; P<0.001; number needed to treat to prevent one primary outcome event, 19 [95% CI, 15 to 27]). The hazard ratio for the composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal causes was 0.56 (95% CI, 0.45 to 0.68; P<0.001), and the hazard ratio for the composite of death from cardiovascular causes or hospitalization for heart failure was 0.71 (95% CI, 0.55 to 0.92; P = 0.009). Death occurred in 101 participants (4.7%) in the dapagliflozin group and 146 participants (6.8%) in the placebo group (hazard ratio, 0.69; 95% CI, 0.53 to 0.88; P = 0.004). The effects of dapagliflozin were similar in participants with type 2 diabetes and in those without type 2 diabetes. The known safety profile of dapagliflozin was confirmed.CONCLUSIONS: Among patients with chronic kidney disease, regardless of the presence or absence o
- Published
- 2020
182. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial:baseline characteristics
- Author
-
Wheeler, David C., Stefansson, Bergur V., Batiushin, Mikhail, Bilchenko, Oleksandr, Cherney, David Z.I., Chertow, Glenn M., Douthat, Walter, Dwyer, Jamie P., Escudero, Elizabeth, Pecoits-Filho, Roberto, Furuland, Hans, Górriz, José Luis, Greene, Tom, Haller, Hermann, Hou, Fan Fan, Kang, Shin Wook, Isidto, Rey, Khullar, Dinesh, Mark, Patrick B., McMurray, John J.V., Kashihara, Naoki, Nowicki, Michal, Persson, Frederik, Correa-Rotter, Ricardo, Rossing, Peter, Toto, Robert D., Umanath, Kausik, Van Bui, Pham, Wittmann, István, Lindberg, Magnus, Sjöström, C. David, Langkilde, Anna Maria, Heerspink, Hiddo J.L., Wheeler, David C., Stefansson, Bergur V., Batiushin, Mikhail, Bilchenko, Oleksandr, Cherney, David Z.I., Chertow, Glenn M., Douthat, Walter, Dwyer, Jamie P., Escudero, Elizabeth, Pecoits-Filho, Roberto, Furuland, Hans, Górriz, José Luis, Greene, Tom, Haller, Hermann, Hou, Fan Fan, Kang, Shin Wook, Isidto, Rey, Khullar, Dinesh, Mark, Patrick B., McMurray, John J.V., Kashihara, Naoki, Nowicki, Michal, Persson, Frederik, Correa-Rotter, Ricardo, Rossing, Peter, Toto, Robert D., Umanath, Kausik, Van Bui, Pham, Wittmann, István, Lindberg, Magnus, Sjöström, C. David, Langkilde, Anna Maria, and Heerspink, Hiddo J.L.
- Abstract
BACKGROUND: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin on kidney and cardiovascular events in participants with CKD with and without type 2 diabetes (T2D). This analysis reports the baseline characteristics of those recruited, comparing them with those enrolled in other trials. METHODS: In DAPA-CKD, 4304 participants with a urinary albumin:creatinine ratio (UACR) ≥200 mg/g and estimated glomerular filtration rate (eGFR) between 25 and 75 mL/min/1.73 m2 were randomized to dapagliflozin 10 mg once daily or placebo. Mean eGFR was 43.1 mL/min/1.73 m2 and median UACR was 949 mg/g (108 mg/mmol). RESULTS: Overall, 2906 participants (68%) had a diagnosis of T2D and of these, 396 had CKD ascribed to a cause other than diabetes. The most common causes of CKD after diabetes (n = 2510) were ischaemic/hypertensive nephropathy (n = 687) and chronic glomerulonephritis (n = 695), of which immunoglobulin A nephropathy (n = 270) was the most common. A total of 4174 participants (97%) were receiving an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, 1882 (43.7%) diuretics, 229 (5.3%) mineralocorticoid receptor antagonists and 122 (2.8%) glucagon-like peptide 1 receptor agonists. In contrast to the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), the DAPA-CKD trial enrolled participants with CKD due to diabetes and to causes other than diabetes. The mean eGFR of participants in the DAPA-CKD trial was 13.1 mL/min/1.73 m2 lower than in CREDENCE, similar to that in the Finerenone in Reducing Kidney Failure and Disease Progression in DKD (FIDELIO-DKD) trial and the Study Of diabetic Nephropathy with AtRasentan (SONAR). CONCLUSIONS: Participants with a wide range of underlying kidney diseases receiving renin-angiotensin system blocking thera
- Published
- 2020
183. Correction of anemia by dapagliflozin in patients with type 2 diabetes
- Author
-
Stefánsson, Bergur V., Heerspink, Hiddo J. L., Wheeler, David C., Sjöström, C. David, Greasley, Peter J., Sartipy, Peter, Cain, Valerie, Correa-Rotter, Ricardo, Stefánsson, Bergur V., Heerspink, Hiddo J. L., Wheeler, David C., Sjöström, C. David, Greasley, Peter J., Sartipy, Peter, Cain, Valerie, and Correa-Rotter, Ricardo
- Abstract
Aims: Anemia is common in type 2 diabetes (T2D), particularly in patients with kidney impairment, and often goes unrecognized. Dapagliflozin treatment increases hemoglobin and serum erythropoietin levels. We investigated the effect of dapagliflozin 10-mg/day on hemoglobin in T2D patients with and without anemia. Methods: Data from 5325 patients from 14 placebo-controlled, dapagliflozin-treatment studies of at least 24-weeks duration were pooled. Dapagliflozin's effects (vs. placebo) on hemoglobin, serum albumin, estimated glomerular filtration rate (eGFR), systolic blood pressure, body weight, and safety in patients with and without anemia were evaluated. Results: At baseline, 13% of all T2D patients and 28% of those with chronic kidney disease (eGFR <60 mL/min/1.73 m2) had anemia. Hemoglobin increased continuously to at least week 8 and was sustained throughout 24-weeks follow-up in dapagliflozin-treated patients. Serum albumin increased in dapagliflozin-treated patients at week 4 and remained stable thereafter. Dapagliflozin was well tolerated and corrected anemia in 52% of patients with anemia at baseline (placebo: 26%). Incidences of new-onset anemia were lower in dapagliflozin-treated (2.3%) versus placebo-treated (6.5%) patients. Conclusions: Treatment with dapagliflozin can correct and prevent anemia in T2D patients. A gradual increase in hemoglobin beyond week 4 may indicate an erythropoiesis-stimulating effect of sodium-glucose cotransporter 2 inhibition.
- Published
- 2020
- Full Text
- View/download PDF
184. Global Kidney Exchange Should Expand Wisely.
- Author
-
Roth, Alvin E, Marino, Ignazio R., Ekwenna, Obi, Dunn, Ty B, Paloyo, Siegfredo R, Tan, Miguel, Correa-Rotter, Ricardo, Kuhr, Christian S, Marsh, Christopher L, Ortiz, Jorge, Testa, Giuliano, Sindhwani, Puneet, Segev, Dorry L, Rogers, Jeffrey, Punch, Jeffrey D, Forbes, Rachel C, Zimmerman, Michael A, Ellis, Matthew J, Rege, Aparna, Basagoitia, Laura, Krawiec, Kimberly D, Rees, Michael A, Roth, Alvin E, Marino, Ignazio R., Ekwenna, Obi, Dunn, Ty B, Paloyo, Siegfredo R, Tan, Miguel, Correa-Rotter, Ricardo, Kuhr, Christian S, Marsh, Christopher L, Ortiz, Jorge, Testa, Giuliano, Sindhwani, Puneet, Segev, Dorry L, Rogers, Jeffrey, Punch, Jeffrey D, Forbes, Rachel C, Zimmerman, Michael A, Ellis, Matthew J, Rege, Aparna, Basagoitia, Laura, Krawiec, Kimberly D, and Rees, Michael A
- Abstract
We read with great interest and appreciation the careful consideration and analysis by Ambagtsheer et al. of the most critical ethical objections to Global Kidney Exchange (GKE). Ambagtsheer et al. conclude that implementation of GKE is a means to increase access to transplantation ethically and effectively.
- Published
- 2020
185. The Role of the Unfolded Protein Response on Renal Lipogenesis in C57BL/6 Mice
- Author
-
Figueroa-Juárez, Elizabeth, primary, Noriega, Lilia G., additional, Pérez-Monter, Carlos, additional, Alemán, Gabriela, additional, Hernández-Pando, Rogelio, additional, Correa-Rotter, Ricardo, additional, Ramírez, Victoria, additional, Tovar, Armando R., additional, Torre-Villalvazo, Iván, additional, and Tovar-Palacio, Claudia, additional
- Published
- 2021
- Full Text
- View/download PDF
186. Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
- Author
-
Koomen, Jeroen V., primary, Stevens, Jasper, additional, Bakris, George, additional, Correa‐Rotter, Ricardo, additional, Hou, Fan Fan, additional, Kitzman, Dalane W., additional, Kohan, Donald E., additional, Makino, Hirofumi, additional, McMurray, John J. V., additional, Parving, Hans‐Henrik, additional, Perkovic, Vlado, additional, Tobe, Sheldon W., additional, Zeeuw, Dick, additional, and Heerspink, Hiddo J. L., additional
- Published
- 2021
- Full Text
- View/download PDF
187. Fibroblast growth factor 21 is associated with increased serum total antioxidant capacity and oxidized lipoproteins in humans with different stages of chronic kidney disease
- Author
-
Gómez-Sámano, Miguel Ángel, primary, Vargas-Abonce, Valerie Paola, additional, Martínez-Sánchez, Froylan David, additional, Palacios-Báez, Lucía, additional, Vera-Zertuche, Juan Mauricio, additional, Navarro-Flores, María Fernanda, additional, Morales-García, Mariana Guadalupe, additional, Fonseca-Correa, Jorge Ignacio, additional, Zuarth-Vázquez, Julia María, additional, Vega-Vega, Olynka, additional, Correa-Rotter, Ricardo, additional, Rincón-Pedrero, Rodolfo, additional, Morales-Buenrostro, Luis E., additional, Alberú-Gómez, Josefina, additional, Ramírez-González, Julia Berenice, additional, Pacheco-Domínguez, Reyna Lizette, additional, López-Cervantes, Malaquías, additional, Mendoza-de-la-Garza, María de los Ángeles, additional, Baeza-Arias, Yolanda Victoria, additional, Espinosa-Cuevas, Ángeles, additional, López-Carrasco, Guadalupe, additional, López-Estrada, Angelina, additional, Guillén-Pineda, Luz Elizabeth, additional, Gómez-Pérez, Francisco Javier, additional, and Cuevas-Ramos, Daniel, additional
- Published
- 2021
- Full Text
- View/download PDF
188. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
- Author
-
Wheeler, David C, primary, Stefánsson, Bergur V, additional, Jongs, Niels, additional, Chertow, Glenn M, additional, Greene, Tom, additional, Hou, Fan Fan, additional, McMurray, John J V, additional, Correa-Rotter, Ricardo, additional, Rossing, Peter, additional, Toto, Robert D, additional, Sjöström, C David, additional, Langkilde, Anna Maria, additional, and Heerspink, Hiddo J L, additional
- Published
- 2021
- Full Text
- View/download PDF
189. Community- and Hospital-Acquired Acute Kidney Injury in COVID-19: Different Phenotypes and Dismal Prognosis
- Author
-
Martínez-Rueda, Armando J., primary, Álvarez, Rigoberto D., additional, Méndez-Pérez, R. Angélica, additional, Fernández-Camargo, Dheni A., additional, Gaytan-Arocha, Jorge E., additional, Berman-Parks, Nathan, additional, Flores-Camargo, Areli, additional, Comunidad-Bonilla, Roque A., additional, Mejia-Vilet, Juan M., additional, Arvizu-Hernandez, Mauricio, additional, Ramirez-Sandoval, Juan C., additional, Correa-Rotter, Ricardo, additional, and Vega-Vega, Olynka, additional
- Published
- 2021
- Full Text
- View/download PDF
190. Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD)
- Author
-
McMurray, John J.v., primary, Wheeler, David C., additional, Stefansson, Bergur V., additional, Correa-Rotter, Ricardo, additional, Chertow, Glenn M., additional, Greene, Tom, additional, Hou, Fan Fan, additional, Lindberg, Magnus B., additional, Rossing, Peter, additional, Sjöström, C. David, additional, Toto, Robert D., additional, Langkilde, Ann Maria, additional, and Heerspink, Hiddo Jl, additional
- Published
- 2020
- Full Text
- View/download PDF
191. Correction of anemia by dapagliflozin in patients with type 2 diabetes
- Author
-
Stefánsson, Bergur V., primary, Heerspink, Hiddo J.L., additional, Wheeler, David C., additional, Sjöström, C. David, additional, Greasley, Peter J., additional, Sartipy, Peter, additional, Cain, Valerie, additional, and Correa-Rotter, Ricardo, additional
- Published
- 2020
- Full Text
- View/download PDF
192. Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial
- Author
-
Koomen, Jeroen V., primary, Stevens, Jasper, additional, Bakris, George, additional, Correa‐Rotter, Ricardo, additional, Hou, Fan Fan, additional, Kitzman, Dalane W., additional, Kohan, Donald, additional, Makino, Hirofumi, additional, McMurray, John J. V., additional, Parving, Hans‐Henrik, additional, Perkovic, Vlado, additional, Tobe, Sheldon W., additional, Zeeuw, Dick, additional, and Heerspink, Hiddo J. L., additional
- Published
- 2020
- Full Text
- View/download PDF
193. Peritoneal Dialysis
- Author
-
Correa-Rotter, Ricardo, primary, Cueto-Manzano, Alfonso, additional, and Khanna, Ramesh, additional
- Published
- 2012
- Full Text
- View/download PDF
194. Contributors
- Author
-
Advani, Andrew, primary, Allon, Michael, additional, Anderson, Amanda Hyre, additional, Appel, Gerald B., additional, Assady, Suheir, additional, Atala, Anthony, additional, Baigent, Colin, additional, Bakkaloglu, Sevcan A., additional, Barletta, Gina-Marie, additional, Becker, Gavin J., additional, Bellomo, Rinaldo, additional, Berns, Jeffrey S., additional, Bhalla, Vivek, additional, Biber, Jürg, additional, Bichet, Daniel G., additional, Bindels, René J.M., additional, Bleicher, Melissa B., additional, Blumenfeld, Jon D., additional, Bonnardeaux, Alain, additional, Bonventre, Joseph V., additional, Boswell, William D., additional, Bowden, Donald W., additional, Brenner, Barry M., additional, Breyer, Matthew D., additional, Breyer, Richard M., additional, Brown, Dennis, additional, Brugnara, Carlo, additional, Bunchman, Timothy E., additional, Bushinsky, David A., additional, Busque, Stéphan, additional, Carrero, Juan Jesús, additional, Cattran, Daniel, additional, Chan, James C., additional, Chandraker, Anil, additional, Chang, Ingrid J., additional, Choudhury, Devasmita, additional, Coe, Fredric L., additional, Collins, John F., additional, Cook, H. Terence, additional, Correa-Rotter, Ricardo, additional, Cowper, Shawn E., additional, Cravedi, Paolo, additional, Cueto-Manzano, Alfonso M., additional, D’Agati, Vivette D., additional, Davids, Mogomat Razeen, additional, Delacroix, Scott E., additional, Denker, Bradley M., additional, Depner, Thomas A., additional, DuBose, Thomas D., additional, Eckardt, Kai-Uwe, additional, Eldehni, Mohamed T., additional, Ellison, David H., additional, Emmett, Michael, additional, Falk, Ronald J., additional, Feldman, Harold I., additional, Fenton, Robert A., additional, Fenves, Andrew Z., additional, Finkel, Kevin W., additional, Fioretto, Paola, additional, Fogarty, Damian G., additional, Foringer, John R., additional, Fouque, Denis, additional, Freedman, Barry I., additional, Frøkiaer, Jørgen, additional, Funder, John W., additional, Game, David S., additional, Gilbert, Richard E., additional, Grantham, Jared J., additional, Halperin, Mitchell L., additional, Hand, Matthew, additional, Hanes, Donna S., additional, Harris, David C.H., additional, Harris, Raymond C., additional, Haynes, Richard, additional, Hoenderop, Joost G.J., additional, Hoorn, Ewout J., additional, Hostetter, Thomas H., additional, Hsu, Chi-yuan, additional, Hua-Lin, Shih, additional, Ibrahim, Hassan N., additional, Israni, Ajay K., additional, Jadvar, Jossein, additional, Jennette, J. Charles, additional, Jonasch, Eric, additional, Kamel, Kamel S., additional, Karumanchi, S. Ananth, additional, Kasiske, Bertram L., additional, Kellum, John A., additional, Kelly, Carolyn J., additional, Khanna, Ramesh, additional, Klassen, David K., additional, Ko, Christine J., additional, Kohli, Harbir Singh, additional, Kost, Curtis K., additional, Krane, L. Spencer, additional, Kreidberg, Jordan, additional, Kwon, Tae-Hwan, additional, Lahoti, Amit, additional, Landray, Martin J., additional, Laragh, John H., additional, Layton, Harold E., additional, Levi, Moshe, additional, Lindholm, Bengt, additional, Liu, Frank, additional, Luyckx, Valerie A., additional, Maddox, David A., additional, Maezawa, Yoshiro, additional, Matas, Arthur J., additional, Mauer, Michael, additional, Maya, Ivan D., additional, Maynard, Sharon E., additional, McDonough, Alicia A., additional, McIntyre, Christopher W., additional, Meyer, Timothy W., additional, Mitch, William E., additional, Moe, Orson W., additional, Moe, Sharon M., additional, Molitoris, Bruce A., additional, Moss, Alvin H., additional, Mount, David B., additional, Munger, Karen A., additional, Nachman, Patrick H., additional, Naicker, Saraladevi, additional, Nielsen, Søren, additional, Neilson, Eric G., additional, Nicolle, Lindsay E., additional, Ornt, Daniel B., additional, Palacín, Manuel, additional, Palevsky, Paul M., additional, Palmer, Suzanne L., additional, Parving, Hans-Henrik, additional, Patrakka, Jaakko, additional, Pearce, David, additional, Pecoits-Filho, Roberto, additional, Peralta, Carmen A., additional, Perico, Norberto, additional, Powe, Neil R., additional, Praditpornsilpa, Kearkiat, additional, Prætorius, Jeppe, additional, Quaggin, Susan E., additional, Quarles, L. Darryl, additional, Radhakrishnan, Jai, additional, Ramadan, Rawi, additional, Reggenenti, Piero, additional, Reich, Heather N., additional, Remuzzi, Andrea, additional, Remuzzi, Giuseppe, additional, Rich, Stephen S., additional, Riella, Miguel C., additional, Ritz, Eberhard, additional, Ronco, Claudio, additional, Rosenblum, Norman D., additional, Rossing, Peter, additional, Rubinger, Dvora, additional, Rude, Robert K., additional, Sabath, Ernesto, additional, Sabbisetti, Venkata, additional, Sakhuja, Vinay, additional, Salama, Alan D., additional, Sands, Jeff M., additional, Santos, Fernando, additional, Sayegh, Mohamed H., additional, Scandling, John D., additional, Schaefer, Franz, additional, Scheinman, Jon I., additional, Schwartz, John C., additional, Sharfuddin, Asif A., additional, Shaw, Susan, additional, Sitprija, Visith, additional, Skorecki, Karl L., additional, Slotki, Itzchak N., additional, Smith, James P., additional, Smogorzewski, Miroslaw J., additional, Sprague, Stuart M., additional, Stenvinkel, Peter, additional, Stokes, John B., additional, Taal, Maarten W., additional, Tamura, Manjula Kurella, additional, Tan, Jane C., additional, Textor, Stephen C., additional, Thadhani, Ravi, additional, Thomson, Scott C., additional, Torres, Vincente E., additional, Tryggvason, Karl, additional, Tuncel, Meryem, additional, Tungsanga, Kriang, additional, Verbalis, Joseph G., additional, Verlander, Jill W., additional, Wadee, Shoyab, additional, Weiner, I. David, additional, Weir, Matthew R., additional, Weisbord, Steven D., additional, Wheeler, David C., additional, Wilcox, Christopher S., additional, Wood, Christopher G., additional, Wright, Stephen H., additional, Yeun, Jane Y., additional, Yu, Alan S.L., additional, Zandi-Nejad, Kambiz, additional, and Zeidel, Mark L., additional
- Published
- 2012
- Full Text
- View/download PDF
195. Association of Vitamin D receptor polymorphisms with osteoporosis in Mexican postmenopausal women
- Author
-
Lisker, Ruben, Lopez, Maria A., Jasqui, Salomon, Rosales, Sergio Ponce De Leon, Correa-Rotter, Ricardo, Sanchez, Sergio, and Mutchinick, Osvaldo M.
- Subjects
Genotype -- Physiological aspects ,Calcifediol -- Physiological aspects ,Alfacalcidol -- Physiological aspects ,Vitamin D -- Physiological aspects ,Human biology -- Research - Abstract
Morrison et al. (1994) reported a strong association between a Vitamin D receptor (VDR) BsmI polymorphism and bone mineral density (BMD) measured at the femoral neck and lumbar spine. Absence […]
- Published
- 2003
196. A soy protein diet alters hepatic lipid metabolism gene expression and reduces serum lipids and renal fibrogenic cytokines in rats with chronic nephrotic syndrome
- Author
-
Tovar, Armando R., Murguia, Fernanda, Cruz, Cristino, Hernandez-Pando, Rogelio, Aguilar-Salinas, Carlos A., Pedraza-Chaverri, Jose, Correa-Rotter, Ricardo, and Torres, Nimbe
- Subjects
Soyfoods -- Health aspects ,Hyperlipidemia -- Physiological aspects ,Proteinuria -- Physiological aspects ,Nephrotic syndrome -- Physiological aspects ,Food/cooking/nutrition - Abstract
Nephrotic syndrome (NS) is characterized by the presence of proteinuria and hyperlipidemia. However, ingestion of soy protein has a hypolipidemic effect. The present study was designed to determine whether the ingestion of a 20% soy protein diet regulates the expression of hepatic sterol regulatory element binding protein (SREBP)-1, fatty acid synthase (FAS), malic enzyme, [beta]-hydroxy-[beta]-methylglutaryl-CoA (HMG-CoA) reductase (r) and synthase (s), and LDL receptor (r), and to assess whether soy protein improves lipid and renal abnormalities in rats with chronic NS. Male Wistar rats were injected with vehicle or with puromycin aminonucleoside to induce NS and were fed either 20% case in or soy protein diets for 64 d. NS rats fed 20% soy protein had improved creatinine clearance and reduced proteinuria, hypercholesterolemia, hypertriglyceridemia, as well as VLDL-triglycerides and LDL cholesterol compared with NS rats fed the 20% casein diet. In addition, the soy protein diet decreased the incidence of glomerular sclerosis, and proinflammatory cytokines in kidney. Ingestion of the soy protein diet by control rats reduced the gene expression of SREBP-1, malic enzyme, FAS and increased HMG-CoAr, HMG-CoAs and LDLr. However, NS rats fed either casein or soy protein diets had low insulin concentrations with reductions in SREBP-1, FAS and malic enzyme expression compared with control rats fed the casein diet. NS rats fed the soy diet also had lower HMG-CoAr and LDLr mRNA levels than NS rats fed casein. In conclusion, the beneficial effects of soy protein on lipid metabolism are modulated in part by SREBP-1. However, in NS rats, the benefit may be through a direct effect of this protein on kidney rather than mediated by changes in expression of hepatic lipid metabolism genes. KEY WORDS: * nephrotic syndrome * lipid metabolism * rats * soy protein * sterol regulatory element binding protein-1
- Published
- 2002
197. Evaluación de la dosis adecuada de diálisis
- Author
-
Correa-Rotter, Ricardo, primary
- Published
- 2009
- Full Text
- View/download PDF
198. Prólogo
- Author
-
Martínez Castelao, Alberto, primary, Rodríguez-Iturbe, Bernardo, additional, and Correa-Rotter, Ricardo, additional
- Published
- 2009
- Full Text
- View/download PDF
199. Diálisis peritoneal en situaciones especiales
- Author
-
Palma, Harold Ayala, primary and Correa-Rotter, Ricardo, additional
- Published
- 2009
- Full Text
- View/download PDF
200. Colaboradores
- Author
-
Melgar, Ángel Alonso, primary, Iraola, Gema Ariceta, additional, Lezama, Javier Arrieta, additional, de Arteaga, Javier, additional, Palma, Harold Ayala, additional, Bajo Rubio, María Auxiliadora, additional, Cabañas, Concepción Blasco, additional, Magariños, Francisco Caravaca, additional, Ribeiro, Silvia Carreira, additional, Díaz, Francisco Coronel, additional, Correa-Rotter, Ricardo, additional, Sanabria, Laura Cortés, additional, Cueto Manzano, Alfonso M., additional, Cusumano, Ana María, additional, López, Edgar Dehesa, additional, Cubells, Teresa Doñate, additional, Ruiz, Evaristo Fernández, additional, García, Manuel García, additional, Ramón, Rafael García, additional, Gil-Cunquero, José Manuel, additional, Gotloib, Lázaro, additional, Luengo, Manuel Lanuza, additional, López Gómez, Juan M., additional, Álvarez, Jesús Loureiro, additional, Fernández, Isabel Martínez, additional, Nihi, Melissa Massaki, additional, de Miguel Carrasco, Alfonso, additional, Pesquera, José Ignacio Minguela, additional, Miguel, Antonio Molina, additional, Martínez, Jesús Montenegro, additional, Molina, Antonio Morey, additional, González, Rosa Inés Muñoz, additional, Arduan, Alberto Ortiz, additional, Acero, Jesús Ángel Padierna, additional, Sierra, José Ramón Paniagua, additional, Filho, Roberto Pecoits, additional, Fontán, Miguel Pérez, additional, García, Rafael Pérez, additional, Pérez-Bañasco, Vicente, additional, del Peso Gilsanz, Gloria, additional, Clemente, Esther Ponz, additional, Portolés Pérez, José M., additional, de Moraes, Thyago Proença, additional, Rodríguez, César Remón, additional, Riella, Miguel Carlos, additional, Gorrín, Maite Rivera, additional, Benítez, Patrocinio Rodríguez, additional, Rodríguez-Carmona, Ana, additional, Campos, Enrique Rojas, additional, Erro, María Concepción Ruiz, additional, de Gauna, Ramón Ruiz, additional, González, Carmen Sánchez, additional, Moreno, Ana Sánchez, additional, Rotaeche, Ramón Saracho, additional, Gutiérrez, Rafael Selgas, additional, Aroeira, Luiz Stark, additional, Planas, Josep Teixidó, additional, Marenco, Felipe Tejuca, additional, Marenco, Mercedes Tejuca, additional, González-Mateo, Guadalupe Tirma, additional, Hernández, Rosario Vázquez, additional, de Jesús Ventura García, María, additional, and Rivera, Manuel Vera, additional
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.